Clinical Trial Update: Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating frontline ibrutinib without corticosteroids for newly diagnosed chronic graft-versus-host disease has completed. Results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic GVHD | Phase 2 | Status: COMPLETED | Results posted: 2025-01-22